<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374994</url>
  </required_header>
  <id_info>
    <org_study_id>0105643</org_study_id>
    <nct_id>NCT04374994</nct_id>
  </id_info>
  <brief_title>Daily Avanafil for Erectile Dysfunction</brief_title>
  <official_title>Evaluation of the Clinical and Molecular Efficacy of Daily Avanafil in Egyptian Males With Erectile and Endothelial Dysfunction (Randomized Placebo-Controlled Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators tried to study the effect of daily avanafil on the serum&#xD;
      level of endothelial function markers, as well as its impact on the erectile function in&#xD;
      males with erectile and endothelial dysfunction by comparing the results with controls who&#xD;
      received placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Avanafil is a highly selective and potent oral phosphodiesterase type 5 inhibitor (PDE5-I) .&#xD;
      However, its impact on the soluble markers of endothelial function has not been investigated&#xD;
      yet. This study was conducted to assess the effect of daily avanafil on the erectile function&#xD;
      and endothelial markers' serum level. In this work we recruited males with erectile&#xD;
      dysfunction and other diseases commonly associated with endothelial dysfunction. The&#xD;
      investigators randomly treated patients with daily oral avanafil and the other patients with&#xD;
      placebo. The investigators measured the International Index of Erectile Function -5 score&#xD;
      (IIEF- 5) and the serum levels of markers of endothelial function at baseline and treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of change of NO serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of Nitric oxide (NO)(in µmol/L) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of change of cGMP serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of cyclic guanosine monophosphate (cGMP) (in pmol/ml) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of change of ET1 serum level from baseline to 4 weeks</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To calculate the percentage of change of endothelin-1 (ET1) (in ng/L) serum level from baseline to 4 weeks post-treatment with avanafil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment NO serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding post-treatment nitric oxide (NO) (in µmol/L) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment cGMP serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding posttreatment cyclic guanosine monophosphate (cGMP) (in pmol/ml) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing avanafil with placebo group regarding post-treatment ET1 serum levels and percentage of change from baseline.</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>To compare avanafil with placebo group regarding post-treatment endothelin-1 (ET1) (in ng/L) serum level and percentage of change from baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measuring the degree of improvement in the IIEF-5 score</measure>
    <time_frame>After 4 weeks treatment</time_frame>
    <description>The ED male's clinical response to daily avanafil was subjectively assessed by measuring the degree of improvement in the International Index of Erectile Function scoring (IIEF-5 ) score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Males with sexual dysfunction who received daily avanafil tablets (50mg) for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Males with sexual dysfunction who received daily placebo tablets for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avanafil 50 MG</intervention_name>
    <description>Oral phosphodiesterase type 5 inhibitors</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose and maize starch, Egypt</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with clinical diagnosis of erectile dysfunction of any severity.&#xD;
&#xD;
          -  Should be associated with systemic disorders indicative of endothelial dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Erectile dysfunction due to psychogenic causes, hypogonadism, or spinal cord injury.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelaal Elkamshoushi, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Alexandria University.</name>
      <address>
        <city>Alexandria</city>
        <state>Elazareta</state>
        <zip>21500</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother. 2009 Feb;10(2):155-60. doi: 10.1517/14656560802678211 .</citation>
    <PMID>19236190</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Shimaa Ismail Abdelhamid, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>erectile dysfunction</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>Avanafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Because we will publish the study in a journal</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04374994/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04374994/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

